At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 355 enrolled
Drug / intervention
TD-4208 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2B, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 2 clinical trial evaluating TD-4208 and Placebo for COPD. Completed, enrolled 355 participants across 1 site.
Detailed Summary
This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesUnited States
CollaboratorsTheravance Biopharma
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartMay 2014
Primary CompletionJul 2014
Study CompletionAug 2014
TodayJul 2026
First PostedJan 20, 2014
Enrollment StartMay 1, 2014
Primary CompletionJul 1, 2014
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.5 years ago
Interventions
TD-4208drug
Placebodrug